These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28301788)

  • 21. [Individual and interdisciplinary treatment of rheumatic diseases in pregnancy].
    Bolz M
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2415. PubMed ID: 18988135
    [No Abstract]   [Full Text] [Related]  

  • 22. Antirheumatic drug therapy during pregnancy.
    Soscia PN; Zurier RB
    Bull Rheum Dis; 1997 Apr; 46(2):2-4. PubMed ID: 9104043
    [No Abstract]   [Full Text] [Related]  

  • 23. The new British Society for Rheumatology disease modifying anti-rheumatic drugs guidelines.
    Deighton C; Gadsby K
    Musculoskeletal Care; 2006 Sep; 4(3):174-81. PubMed ID: 17042028
    [No Abstract]   [Full Text] [Related]  

  • 24. Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.
    Schulze-Koops H
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv1-iv3. PubMed ID: 28903541
    [No Abstract]   [Full Text] [Related]  

  • 25. [Current status of methotrexate].
    Fiehn C
    Z Rheumatol; 2011 Feb; 70(2):99-100. PubMed ID: 21312022
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacogenetics in the rheumatic diseases.
    Cronstein BN
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii25-ii27. PubMed ID: 15479867
    [No Abstract]   [Full Text] [Related]  

  • 27. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
    Yelin E; Katz P
    Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
    [No Abstract]   [Full Text] [Related]  

  • 28. Bibliography. Current world literature. Clinical therapeutics.
    Curr Opin Rheumatol; 2008 May; 20(3):360-6. PubMed ID: 18388531
    [No Abstract]   [Full Text] [Related]  

  • 29. [Fetal safety profile of drugs used in the treatment of inflammatory rheumatic diseases].
    Falcão S; Mourão AF; Pimentão JB; Branco JC
    Acta Reumatol Port; 2007; 32(4):323-31. PubMed ID: 18159198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reproductive Rheumatology: Meeting Today's Challenges.
    Sammaritano LR; Chakravarty EF
    Rheum Dis Clin North Am; 2017 May; 43(2):xiii-xiv. PubMed ID: 28390572
    [No Abstract]   [Full Text] [Related]  

  • 31. Robin Goodfellow.
    Rheumatology (Oxford); 2001 Nov; 40(11):1322. PubMed ID: 11709624
    [No Abstract]   [Full Text] [Related]  

  • 32. Disease modifying antirheumatic drugs and pregnancy.
    Uhl K; Kennedy DL; Gilliland WR
    J Rheumatol; 2004 Feb; 31(2):400-1; author reply 401-2. PubMed ID: 14760818
    [No Abstract]   [Full Text] [Related]  

  • 33. Antirheumatic drugs in pregnancy.
    Harris EN
    Lupus; 2002; 11(10):683-9. PubMed ID: 12413069
    [No Abstract]   [Full Text] [Related]  

  • 34. Advances in Targeted Therapies VI. Proceedings of the 6th International Symposium. Venice, Italy, 28 April-2 May 2004.
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2():ii1-101. PubMed ID: 15479863
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pregnancy in rheumatic patients treated with biologic drugs].
    Sentić M; Baresić M; Anić B; Bosnić D; Cerovec M; Mayer M; Smiljanić L; Cikes N
    Lijec Vjesn; 2010; 132(9-10):317-8. PubMed ID: 21261033
    [No Abstract]   [Full Text] [Related]  

  • 36. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs.
    Ledingham J; Gullick N; Irving K; Gorodkin R; Aris M; Burke J; Gordon P; Christidis D; Galloway S; Hayes E; Jeffries A; Mercer S; Mooney J; van Leuven S; Galloway J;
    Rheumatology (Oxford); 2017 Jun; 56(6):865-868. PubMed ID: 28339817
    [No Abstract]   [Full Text] [Related]  

  • 37. [Biological treatment of rhematoid diseases].
    Pavelka K
    Vnitr Lek; 2006 Jun; 52(6):561-2. PubMed ID: 16871758
    [No Abstract]   [Full Text] [Related]  

  • 38. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research.
    Gasparyan AY; Ayvazyan L; Cocco G; Kitas GD
    Curr Pharm Des; 2012; 18(11):1543-55. PubMed ID: 22364138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists.
    Gossec L; Bijlsma JW; Bombardier C; Canhão H; Devlin J; Edwards CJ; Hamuryudan V; Kvien TK; Leeb BF; Martín-Mola EM; Mielants H; Müller-Ladner U; Ostergaard M; Pereira IA; Ramos-Remus C; Zochling J; Dougados M
    Ann Rheum Dis; 2011 Feb; 70(2):388-9. PubMed ID: 20472594
    [No Abstract]   [Full Text] [Related]  

  • 40. [Sulphasalazine: a promising drug in rheumatology].
    Nasonov EL
    Klin Med (Mosk); 1997; 75(6):39-44. PubMed ID: 9273399
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.